The Bill & Melinda Gates Foundation, in its COVID-19 response, will fund up to $120 million to ensure access in lower-income countries to Merck & Co.’s experimental oral drug, the foundation announced on Oct. 19.
The funding will support efforts to develop and produce generic versions of what could become the first oral antiviral medication for the disease if it wins regulatory approval, according to a statement from the foundation.
